Cargando…

The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter

BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions...

Descripción completa

Detalles Bibliográficos
Autores principales: Barton, Jennifer L, Koenig, Christopher J, Evans-Young, Gina, Trupin, Laura, Anderson, Jennie, Ragouzeos, Dana, Breslin, Maggie, Morse, Timothy, Schillinger, Dean, Montori, Victor M, Yelin, Edward H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363399/
https://www.ncbi.nlm.nih.gov/pubmed/25649726
http://dx.doi.org/10.1186/s12911-014-0104-8
_version_ 1782361907562283008
author Barton, Jennifer L
Koenig, Christopher J
Evans-Young, Gina
Trupin, Laura
Anderson, Jennie
Ragouzeos, Dana
Breslin, Maggie
Morse, Timothy
Schillinger, Dean
Montori, Victor M
Yelin, Edward H
author_facet Barton, Jennifer L
Koenig, Christopher J
Evans-Young, Gina
Trupin, Laura
Anderson, Jennie
Ragouzeos, Dana
Breslin, Maggie
Morse, Timothy
Schillinger, Dean
Montori, Victor M
Yelin, Edward H
author_sort Barton, Jennifer L
collection PubMed
description BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming, especially for those with limited literacy or limited English language proficiency. The objective of this study is to describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three languages using low literacy principles. METHODS: Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A combination of evidence synthesis and direct observation of clinician-patient interactions generated content and guided an iterative process of prototype development. RESULTS: Three iterations of RA Choice were developed and field-tested before completion. The final tool organized data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician and patient, and garnered high acceptability from clinicians. CONCLUSIONS: The process of collaboratively developing an RA decision aid designed to promote shared decision making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the potential to enhance communication for RA patients, including those with limited health literacy and limited English language proficiency.
format Online
Article
Text
id pubmed-4363399
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43633992015-03-19 The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter Barton, Jennifer L Koenig, Christopher J Evans-Young, Gina Trupin, Laura Anderson, Jennie Ragouzeos, Dana Breslin, Maggie Morse, Timothy Schillinger, Dean Montori, Victor M Yelin, Edward H BMC Med Inform Decis Mak Research Article BACKGROUND: Shared decision-making in rheumatoid arthritis (RA) care is a priority among policy makers, clinicians and patients both nationally and internationally. Demands on patients to have basic knowledge of RA, treatment options, and details of risk and benefit when making medication decisions with clinicians can be overwhelming, especially for those with limited literacy or limited English language proficiency. The objective of this study is to describe the development of a medication choice decision aid for patients with rheumatoid arthritis (RA) in three languages using low literacy principles. METHODS: Based on the development of a diabetes decision aid, the RA decision aid (RA Choice) was developed through a collaborative process involving patients, clinicians, designers, decision-aid and health literacy experts. A combination of evidence synthesis and direct observation of clinician-patient interactions generated content and guided an iterative process of prototype development. RESULTS: Three iterations of RA Choice were developed and field-tested before completion. The final tool organized data using icons and plain language for 12 RA medications across 5 issues: frequency of administration, time to onset, cost, side effects, and special considerations. The tool successfully created a conversation between clinician and patient, and garnered high acceptability from clinicians. CONCLUSIONS: The process of collaboratively developing an RA decision aid designed to promote shared decision making resulted in a graphically-enhanced, low literacy tool. The use of RA Choice in the clinical encounter has the potential to enhance communication for RA patients, including those with limited health literacy and limited English language proficiency. BioMed Central 2014-11-25 /pmc/articles/PMC4363399/ /pubmed/25649726 http://dx.doi.org/10.1186/s12911-014-0104-8 Text en © Barton et al.; licensee BioMed Central. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Barton, Jennifer L
Koenig, Christopher J
Evans-Young, Gina
Trupin, Laura
Anderson, Jennie
Ragouzeos, Dana
Breslin, Maggie
Morse, Timothy
Schillinger, Dean
Montori, Victor M
Yelin, Edward H
The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title_full The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title_fullStr The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title_full_unstemmed The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title_short The design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
title_sort design of a low literacy decision aid about rheumatoid arthritis medications developed in three languages for use during the clinical encounter
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4363399/
https://www.ncbi.nlm.nih.gov/pubmed/25649726
http://dx.doi.org/10.1186/s12911-014-0104-8
work_keys_str_mv AT bartonjenniferl thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT koenigchristopherj thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT evansyounggina thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT trupinlaura thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT andersonjennie thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT ragouzeosdana thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT breslinmaggie thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT morsetimothy thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT schillingerdean thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT montorivictorm thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT yelinedwardh thedesignofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT bartonjenniferl designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT koenigchristopherj designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT evansyounggina designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT trupinlaura designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT andersonjennie designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT ragouzeosdana designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT breslinmaggie designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT morsetimothy designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT schillingerdean designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT montorivictorm designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter
AT yelinedwardh designofalowliteracydecisionaidaboutrheumatoidarthritismedicationsdevelopedinthreelanguagesforuseduringtheclinicalencounter